A Flow Cytometry Method for Rapidly Assessing Mycobacterium tuberculosis Responses to Antibiotics with Different Modes of Action

Antimicrob Agents Chemother. 2016 Jun 20;60(7):3869-83. doi: 10.1128/AAC.02712-15. Print 2016 Jul.

Abstract

Current methods for assessing the drug susceptibility of Mycobacterium tuberculosis are lengthy and do not capture information about viable organisms that are not immediately culturable under standard laboratory conditions as a result of antibiotic exposure. We have developed a rapid dual-fluorescence flow cytometry method using markers for cell viability and death. We show that the fluorescent marker calcein violet with an acetoxy-methyl ester group (CV-AM) can differentiate between populations of M. tuberculosis growing at different rates, while Sytox green (SG) can differentiate between live and dead mycobacteria. M. tuberculosis was exposed to isoniazid or rifampin at different concentrations over time and either dual stained with CV-AM and SG and analyzed by flow cytometry or plated to determine the viability of the cells. Although similar trends in the loss of viability were observed when the results of flow cytometry and the plate counting methods were compared, there was a lack of correlation between these two approaches, as the flow cytometry analysis potentially captured information about cell populations that were unable to grow under standard conditions. The flow cytometry approach had an additional advantage in that it could provide insights into the mode of action of the drug: antibiotics targeting the cell wall gave a flow cytometry profile distinct from those inhibiting intracellular processes. This rapid drug susceptibility testing method could identify more effective antimycobacterials, provide information about their potential mode of action, and accelerate their progress to the clinic.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antitubercular Agents / pharmacology*
  • Ciprofloxacin / pharmacology
  • Flow Cytometry / methods*
  • Isoniazid / pharmacology
  • Kanamycin / pharmacology
  • Microbial Sensitivity Tests / methods*
  • Mycobacterium tuberculosis / drug effects*
  • Rifampin / pharmacology

Substances

  • Antitubercular Agents
  • Kanamycin
  • Ciprofloxacin
  • Isoniazid
  • Rifampin

Grants and funding

The research leading to these results has received funding from the Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115337, resources of which are composed of financial contributions from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in-kind contribution. Funding was also received from a Department of Health Grant in Aid and the National Institute of Health Research. The views expressed in this publication are those of the authors and not necessarily those of Public Health England, the National Institute for Health Research, or the Department of Health.